glioma/únava organizmu

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 119 výsledky

Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Fatigue is the most prevalent and disabling symptom in cancer patients. Yet, scientific literature on this topic is scarce and reports disparate results. This study systematically reviews how fatigue is assessed in patients with low-grade glioma and evaluates its prevalence in LGG patients. A

Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Diffuse intrinsic pontine glioma (DIPG) is an incurable disease with a median overall survival of 10 months. Immune modulating antibodies have recently emerged as a highly promising treatment modality in multiple cancer types. We present results from the first study to evaluate the immune modulating

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Preclinical activity of irinotecan has been seen in glioma models, but only modest efficacy has been noted in clinical studies, perhaps related to drug distribution and/or pharmacokinetic limitations. In preclinical testing, irinotecan liposome injection (nal-IRI) results in prolongation of drug

Prospective study of quality of life in adults with newly diagnosed high-grade gliomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To assess baseline quality of life (QOL) and its prognostic importance for adults with newly diagnosed high-grade gliomas, we analyzed QOL and outcome data prospectively collected in three phase II high-grade glioma protocols. METHODS At study entry, patients completed five

A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To determine the response rate, time to disease progression, survival, and toxicity of intravenous carboplatin and chronic oral high-dose tamoxifen in patients with recurrent malignant gliomas. METHODS Patients with histological confirmation of recurrent malignant gliomas were eligible for

Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

In the 1950's it was first observed that mammalian cells exposed to the halogenated deoxyuridines were more sensitive to ultraviolet light and radiation than untreated cells. This prompted early clinical trials with bromodeoxyuridine (BUdR) which showed mixed results. More recently, several Phase I

Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Bevacizumab, a humanized recombinant anti-vascular endothelial growth factor antibody, was approved in Canada in 2010 for the treatment of high-grade glioma. We report the effectiveness and safety of bevacizumab in the treatment of patients with recurrent high-grade gliomas at a single

The ocular effects of intracarotid bromodeoxyuridine and radiation therapy in the treatment of malignant glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Since July 1985, 23 patients have been entered into a phase I/II clinical trial using intraarterial 5-bromodeoxyuridine (BUdR) (400-600 mg/m2 daily for 8.5 weeks) and focal external beam radiotherapy (59.4 Gy at 1.8 Gy daily in 6.5 weeks) in the treatment of malignant gliomas (Kernohan grades 3 and

Palliative reirradiation for progressive diffuse intrinsic pontine glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE Diffuse intrinsic pontine gliomas (DIPGs) are highly aggressive tumors and have a poor prognosis. Nearly all patients experience disease progression after definitive treatment, accompanied by severe neurologic deficits and morbidity. Here, we report a series of patients treated with

[Coping in patients with malignant glioma in the course of radiation therapy].

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Twenty-one patients with malignant glioma were interviewed in the course of radiation therapy (before start, in the middle and at the end of treatment and six weeks later). We used the "Freiburger Fragebogen zur Krankheitsverarbeitung (FKV)", an assessment of coping strategies, the

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. METHODS Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients.

Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas. Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this

A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This phase II study in recurrent high-grade glioma evaluated the response rate, toxicities, and time to treatment failure of high-dose carboplatin modulated by a 24-h infusion of thymidine (75 g/m(2)). The trial was based on preclinical data and a prior phase I study ( J. Clin. Oncol. 17, 2922-2931,

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent. METHODS Adult patients with recurrent malignant glioma were

First experiences in treatment of low-grade glioma grade I and II with proton therapy.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II). METHODS Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases

Predchádzajúce
1
2
3
4
5
6
7
8
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume